Trial reportScience translational medicine2019
A variant erythroferrone disrupts iron homeostasis in
Open access · greenAbstract readClinical Trial
In one paragraph
Trial report in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 80 citations in OpenAlex.
- Molecular Mechanisms of Iron Metabolism and Overload.Biomedicines · 2025Review
- Distinct routes of clonal progression in SF3B1-mutant myelodysplastic syndromes.Blood advances · 2025Article
- Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects.Biomolecules · 2025Review
- Low-risk MDS-A spotlight on precision medicine forHemaSphere · 2025Review
- SF3B1: from core splicing factor to oncogenic driver.RNA (New York, N.Y.) · 2025Review
- Iron-Loading Anemias.Advances in experimental medicine and biology · 2025Review
- [Research progress of iron metabolism and ferroptosis in myeloid neoplasms].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
- Erythroferrone in focus: emerging perspectives in iron metabolism and hematopathologies.Blood science (Baltimore, Md.) · 2024Review
- Mis-splicing of Mitotic Regulators Sensitizes SF3B1-Mutated Human HSCs to CHK1 Inhibition.Blood cancer discovery · 2024Article
- The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.Blood advances · 2024Article
- Review
- Role of reactive oxygen species in myelodysplastic syndromes.Cellular & molecular biology letters · 2024Review
- Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.Nature communications · 2024Article
- Article
- Alternative splicing and related RNA binding proteins in human health and disease.Signal transduction and targeted therapy · 2024Review
- Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.Cancer research · 2024Article
- The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies.Cancers · 2024Review
- Understanding iron homeostasis in MDS: the role of erythroferrone.Frontiers in oncology · 2024Review
- Mutant SF3B1 promotes malignancy in PDAC.eLife · 2023Article
- Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.Blood advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 16 institutions in 5 countries.
Sabrina BonduUniversité de Paris, Paris 75006, France.ORCID 0000-0003-3472-7681
Anne-Sophie AlaryUniversité de Paris, Paris 75006, France.ORCID 0000-0001-9336-6869
Carine LefèvreUniversité de Paris, Paris 75006, France.ORCID 0000-0003-3590-2445
Alexandre HouyInstitut Curie, PSL Research University, Human Genetics and Oncogenesis, Paris 75005, France.ORCID 0000-0001-6267-2353
Grace JungDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-7106-5069
Thibaud LefebvreUniversité de Paris, Paris 75006, France.ORCID 0000-0003-1398-6473
David RombautUniversité de Paris, Paris 75006, France.ORCID 0000-0001-8910-0945
Ismael BoussaidUniversité de Paris, Paris 75006, France.
Abderrahmane BoustaUniversité de Paris, Paris 75006, France.ORCID 0000-0002-7187-6486
François GuillonneauUniversité de Paris, Paris 75006, France.ORCID 0000-0003-1484-4696
Prunelle PerrierInstitut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM U1220, Institut National de la Recherche Agronomique U1416, Ecole Nationale Vétérinaire de Toulouse, Université Paul Sabatier, Toulouse 31024, France.
Samar AlsafadiInstitut Curie, PSL Research University, Department of Translational Research, Paris 75005, France.ORCID 0000-0002-0060-1346
Michel WassefInstitut Curie, PSL Research University, INSERM 934/UMR 3215, Genetics and biology of Development, Paris 75005 France.
Raphaël MargueronInstitut Curie, PSL Research University, INSERM 934/UMR 3215, Genetics and biology of Development, Paris 75005 France.
Alice RousseauUniversité de Paris, Paris 75006, France.
Nathalie DroinInstitut Gustave Roussy, Genomic platform, Villejuif 94805, France.ORCID 0000-0002-6099-5324
Nicolas CagnardUniversité de Paris, Paris 75006, France.ORCID 0000-0002-9051-1896
Sophie KaltenbachUniversité de Paris, Paris 75006, France.
Susann WinterMedical Clinic und Policlinic 1, Technische Universität Dresden, Dresden 01307, Germany.
Anne-Sophie KubaschMedical Clinic und Policlinic 1, Hematology and Cellular Therapy, University Hospital, Leipzig 04103, Germany.
Didier BouscaryUniversité de Paris, Paris 75006, France.
Valeria SantiniMDS unit, Hematology, AOU Careggi, University of Florence, Florence 50134, Italy.
Andrea TomaDépartement d'Hématologie, AP-HP, Hôpital Henri-Mondor, Université Paris 12, Créteil 94000, France.
Mathilde HunaultService des Maladies du Sang, Centre hospitalo-universitaire, Angers 49100, France.
Aspasia StamatoullasDépartement d'hématologie, Centre Henri-Becquerel, Rouen 76038, France.
Emmanuel GyanService d'hématologie et thérapie cellulaire, Centre hospitalo-universitaire, CNRS ERL 7001 LNOx, Université de Tours, Tours 37044, France.ORCID 0000-0002-7651-9189
Thomas CluzeauCôte d'Azur University, CHU of Nice, Hematology department and INSERM U1065, Mediterranean Center of Molecular Medecine, Nice 06204, France.
Uwe PlatzbeckerMedical Clinic und Policlinic 1, Hematology and Cellular Therapy, University Hospital, Leipzig 04103, Germany.
Lionel AdèsUniversité de Paris, Paris 75006, France.ORCID 0000-0002-9020-8766
Hervé PuyUniversité de Paris, Paris 75006, France.
Marc-Henri SternInstitut Curie, PSL Research University, INSERM U830, Genetics and biology of cancers, DNA repair and uveal melanoma (D.R.U.M.), Équipe labellisée par la Ligue nationale contre le cancer, Paris 75005, France.
Zoubida KarimUniversité de Paris, Paris 75006, France.
Patrick MayeuxUniversité de Paris, Paris 75006, France.
Elizabeta NemethDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-3477-2397
Sophie ParkDépartement d'Hématologie, Centre Hospitalier Universitaire, Université de Grenoble Alpes, La Tronche 38700, France.ORCID 0000-0003-0514-5789
Tomas GanzDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-2830-5469
Léon KautzInstitut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM U1220, Institut National de la Recherche Agronomique U1416, Ecole Nationale Vétérinaire de Toulouse, Université Paul Sabatier, Toulouse 31024, France.ORCID 0000-0002-2320-0457
Olivier KosmiderUniversité de Paris, Paris 75006, France. michaela.fontenay@inserm.fr olivier.kosmider@aphp.fr.ORCID 0000-0002-6021-4057
Michaëla FontenayUniversité de Paris, Paris 75006, France. michaela.fontenay@inserm.fr olivier.kosmider@aphp.fr.ORCID 0000-0002-5492-6349
Centre National de la Recherche Scientifique · FRInserm · FRUniversity of California, Los Angeles · USUniversité Paris Cité · FRUniversité Paris Sciences et Lettres · FRUniversité Toulouse III - Paul Sabatier · FRUniversity Hospital Leipzig · DEAzienda Ospedaliero-Universitaria Careggi · ITCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Grenoble · FRHôpital Necker-Enfants Malades · FRInstitut Gustave Roussy · FRLaboratoire National Henri Becquerel · FRTechnische Universität Dresden · DEUniversité de Tours · FRUniversité Paris-Est Créteil · FR
Funding
UC BRAID Center for Accelerated Innovation COVID-19 diagnostic project developmentU54HL119893 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PALAZZOLO, MICHAEL J · 2013 to 2020
$18.3MThe role of erythroferrone in iron homeostasis and in iron-loading anemiasR01DK065029 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GANZ, TOMAS · 2004 to 2017
$4.9MNHLBI NIH HHS U54 HL119893NIDDK NIH HHS R01 DK065029
Abstract
Myelodysplastic syndromes (MDS) with ring sideroblasts are hematopoietic stem cell disorders with erythroid dysplasia and mutations in the
Indexed as
HomeostasisAlternative SplicingAmino Acid SequenceAnimalsBlood TransfusionCell LineCell LineageCell SurvivalClone CellsErythroid CellsHepcidinsHumansIronLenalidomideMiceMutationErfe protein, humanHepcidinsIronLenalidomidePeptide HormonesPhosphoproteinsRNA, MessengerRNA Splice SitesRNA Splicing FactorsSF3B1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.